The European Commission is reportedly set to investigate Johnson & Jonson and Novartis over claims the two pharmaceutical companies partook in anticompetitive policies and practices through squeezing out a generic painkiller competitor. The allegations consist of the companies’ Dutch subsidiaries colluding to keep generic fentanyl off the shelves after J&J’s patent protection on the branded drug expired. The EC has reportedly filed its first action against the companies in the form of a statement of objections. These types of pay-for-delay agreements have been under consideration from the Commission for several years; an industry-wide probe into the matter began in 2008.
Full content: PMLive
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
Elon Musk Leads $97.4 Billion Bid to Take Control of OpenAI
Feb 10, 2025 by
CPI
Nigerian Court Confirms Consumer Protection Commission’s Authority Over Telecom Sector
Feb 10, 2025 by
CPI
Microsoft Under French Antitrust Investigation Over Bing Practices
Feb 10, 2025 by
CPI
Hausfeld Grows Antitrust Litigation Team
Feb 10, 2025 by
CPI
Microsoft Seeks to Ease EU Antitrust Concerns With Office Pricing Adjustment
Feb 10, 2025 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – International Criminal Enforcement
Jan 23, 2025 by
CPI
The Antitrust Division’s Recent Work to Combat International Cartels
Jan 23, 2025 by
Emma Burnham & Benjamin Christenson
Information Sharing: The New Frontier of U.S. Antitrust Enforcement
Jan 23, 2025 by
Brian P. Quinn, Casey Kovarik & Michael Tubach
The Key Role of Guidelines on Exchanges of Information Among Competitors and the Divergent Transatlantic Paths
Jan 23, 2025 by
Rosa Abrantes-Metz & Albert Metz
Leniency, Whistleblowers, and Compliance
Jan 23, 2025 by
Richard Powers, Tara O’Malley & Cory Gordon